Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review

BACKGROUND: The evidence base for optimum third-line therapy for metastatic colorectal cancer (mCRC) is not conclusive. Recent studies have demonstrated the efficacy of regorafenib as third-line therapy in mCRC. This indirect meta-analysis compared the efficacy and safety of regorafenib with other a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yinying, Fan, Yangwei, Dong, Danfeng, Dong, Xuyuan, Hu, Yuan, Shi, Yu, Jing, Jiayu, Li, Enxiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364795/
https://www.ncbi.nlm.nih.gov/pubmed/32728393
http://dx.doi.org/10.1177/1758835920940932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364795/
https://www.ncbi.nlm.nih.gov/pubmed/32728393
http://dx.doi.org/10.1177/1758835920940932

Ejemplares similares